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Abstract
Background: Oxidative stress could play a role in pathogenesis of hepatitis C virus (HCV)
infection. The aim of our study is to determine oxidant/antioxidant status of patients with chronic
hepatitis C (CHC), and the effect of pegylated interferon alfa-2b plus ribavirin combination therapy
on oxidative stress.
Methods: Nineteen patients with chronic HCV infection and 28 healthy controls were included in
the study. In control and patient groups, serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) levels, erythrocyte malondialdehyde (MDA) levels, erythrocyte CuZn-
superoxide dismutase (SOD), erythrocyte glutathione peroxidase (GSH-Px) activities were
measured. After pegylated interferon alfa-2b and ribavirin combination therapy for 48 weeks, these
parameters were measured again in the patient group.
Results: Serum MDA levels increased significantly in CHC patients (n:19), before the treatment
when compared with healthy subjects (n:28) 9.28 ± 1.61, 4.20 ± 1.47 nmol/ml, p < 0.001
respectively. MDA concentration decreased significantly (p < 0.001) after the treatment as well as
ALT, AST activity, in erythrocytes of these patients. Average antioxidant enzymes (superoxide
dismutase and glutathione peroxidase) were significantly lower in erythrocytes of patients with
CHC before treatment compared with the control group (both, p < 0.001). Chronic Hepatitis C
patients after pegylated interferon alfa-2b and ribavirin therapy showed values of SOD, GSH-Px
were significantly higher than pretreatment levels (both, p < 0.001).
Conclusion: Our results show that patients with chronic HCV infection are under the influence
of oxidative stress associated with lower levels of antioxidant enzymes. These impairments return
to level of healthy controls after pegylated interferon alfa-2b plus ribavirin combination therapy of
CHC patients. Although interferon and ribavirin are not antioxidants, their antiviral capacity might
reduce viral load, and inflammation, and perhaps through this mechanism might reduce virus-
induced oxidative stress.
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Hepatitis C virus (HCV) is one of the main causative
agents of chronic viral hepatitis. Chronic hepatitis C can
progress to cirrhosis and eventually to hepatocellular car-
cinoma over a period of 20 to 30 years. The mechanisms
by which HCV causes cell damage are not well under-
stood. Different mechanisms including immunological
liver damage, direct cytotoxicity mediated by different
viral product and inductions of oxidative stress have been
suggested as playing a pathogenic role in this infection
[1]. It has been suggested that HCV may cause oxidative
stress in infected cell. Several lines of evidence support
this contention, including the existence of activated glu-
tathione turnover, the presence of increased levels of lipid
peroxidation products and augmented iron stores in the
liver, and the finding of diminished reduced glutathione
values in peripheral blood mononuclear cells and erythro-
cytes. Moreover, it has been showed that patients with
chronic hepatitis C exhibit an increased production of
tumor necrosis factor-alfa (TNF-α), a cytokine that can
produce oxidative stress by simulating the generation of
reactive oxygen species (ROS) such as superoxide ion (O2.-
) and hydrogen peroxide (H2O2). ROS can damage cells
by causing lipid peroxidation, and oxidative damage of
DNA and proteins, and by depleting ATP stores. In the
presence of metals (such as Fe 3+), O2.- can react with H2O2
to generate a hydroxyl radical than become even more
reactive and cytototoxic than O2.- or H2O2 [2].
Lipid peroxidation is caused by free radicals leading to
oxidative destruction of polyunsaturated fatty acids con-
stitutive of cellular membranes. Their destruction leads to
the production of toxic and reactive aldehyde metabolites
such as malondialdehyde (MDA) and 4-hydroxynonenal
(HNE). These highly cytotoxic metabolites, produced in
relatively large amounts, can diffuse from their site of ori-
gin to attack distant targets and form covalent bonds with
various molecules. Therefore, recognition of lipid peroxi-
dation is of interest, as the deleterious effects of this proc-
ess, including fibrogenesis, might be prevented by
administration of scavenging systems or antioxidants.
Most previous studies investigating lipid peroxidation
dealt with blood and tissue extracts by indirect quantita-
tive methods; the thiobarbituric acid test has been the
most commonly applied. Using this procedure, an
increase in MDA was observed in the serum, and the liver
of patients with chronic hepatitis C. Recently, specific
antibodies against MDA and HNE adducts have been
raised [3].
Cells are protected against oxidative insults by natural
antioxidant products, notably glutathione, and by diverse
antioxidant enzymes such as superoxide dismutase
(SOD), catalase (CAT) and glutathione peroxidase (GSH-
Px) [2]. Oxidative stress develops when the disturbance in
balance between the reactive oxygen forms produced in
excess, and the factors preventing their harmful effect
occur.
Researchers revealed that ROS might be one of the causes
of gastrointestinal tract diseases, for example; acute pan-
creatitis, ulcerative colitis or chronic peptic or duodenal
ulcer disease. A significant role of ROS was demonstrated
in non-viral hepatitis, especially in hemochromatosis,
Wilson disease, and alcoholic lesion of the liver [4].
Although the main role of immunological mechanisms in
pathogenesis of chronic viral hepatitis B and C were dem-
onstrated, researchers also concentrate on the problem of
oxidative stress in pathology of the diseases.
Many attempts have been made to find serological or cel-
lular markers that help in the clinical management and
evaluation of treatment response of chronic hepatitis C
(CHC) patients, including plasma viral load, plasma anti-
HCV IgM or other soluble immune factors, hepatic viral
RNA, etc.; however, repeated biopsies are needed to eval-
uate disease progression [5]. Although interferon-alfa is
still used in treatment of chronic viral hepatitis, its effect
on the oxidant and antioxidant status of patients is not
well known, which may be significant in deciding on the
type on therapy, follow-up and prognosis of patients. The
aim of our study is to determine the role of oxidative stress
on hepatic damage in the patients with the chronic hepa-
titis C virus infection and the effect of pegylated interferon




Nineteen patients (11 males and 8 females), mean age 38
± 12 years, with chronic HCV infection were included in
this study. The infection group was selected for this study
from out patient clinic unit of the Gülhane Military Med-
ical Academy (GMMA) infectious diseases department.
Diagnosis of chronic hepatitis C was based on elevation of
serum transaminases, positivity for anti-HCV antibodies
(ELISA second generation Ortho Diagnostic Systems, Rar-
itan, NJ), and presence of HCV-RNA (reverse transcrip-
tion-PCR) in serum and histological evidence of chronic
hepatitis. The patients with other chronic or autoimmune
liver diseases were excluded from the study.
Control group
The control group (CG) consisting of 28 healthy individ-
uals (18 males and 10 females), mean age 26.67 ± 6.14
years, were selected from voluntary blood donors of the
GMMA. They were selected on the basis of general physi-
cal examination. They were seronegative for HCV, HBV,
HIV, HBsAg, anti-HBc total, and anti-HCV tests were neg-Page 2 of 6
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and/or chronic alcoholism was evident. They showed no
abnormal laboratory findings including liver function
tests. They also showed normal levels of aminotrans-
ferase. Informed consent was obtained from each patient,
and control group individuals.
Pegylated interferon alfa-2b and ribavirin treatment
The selected patients above received pegylated interferon
alfa-2b, 1.5 µg/kg subcutaneous weekly, and ribavirin 200
mg capsules (dose: <75 kg BW: 2 caps in a.m. & 3 caps in
p.m., >75 kg BW: 3 caps in a.m. & 3 caps in p.m.) for 48
weeks. After pegylated interferon alfa-2b and ribavirin
therapy, patients showed normalized serum transaminase
and negative HCV-RNA. In control and patient groups,
serum alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) levels, erythrocyte MDA levels, eryth-
rocyte CuZn-SOD and erythrocyte GSH-Px activities were
measured. In the patient group, these parameters were
measured again after the completion of therapy.
Laboratory method
Blood samples were drawn from the antecubital vein fol-
lowing an overnight fast, by venipuncture into tubes con-
taining EDTA. They were centrifuged for 10 min. at 4000
g and 4°C. After separation of the plasma, the buffy coat
was removed and the packed cells washed three times
with two volumes of isotonic saline. Then, a known vol-
ume of erythrocytes was lysed with cold distilled water
(1:4), stored in a refrigerator at 4°C for 15 min. and the
cell debris were removed by centrifugation (2000 g at 4°C
for 10 min.). The erythrocyte lysates were stored at -70°C
until assayed.
CuZn-SOD and GSH-Px activities were measured in the
erythrocyte lysates on a UV-VIS Recording Spectropho-
tometer (UV-2100S, Shimadzu Co., Kyoto, Japan).
Erythrocyte CuZn-SOD activity was measured as previ-
ously described by Aydin et al. [6]. Briefly, the erythrocyte
lysates were diluted 400-fold with 10 mM phosphate
buffer, pH 7.00. 25-µl aliquots were mixed with 850 µl of
substrate solution containing 0.05 mmol/L xanthine
sodium and 0.025 mmol/L 2-(4-iodophenyl)-3-(4-nitro-
phenol)-5-phenyltetrazolium chloride (INT) in a buffer
solution containing 50 mmol/L CAPS (3-(cyclohexylami-
nol)-1-propanesulfonic acid) and 0.094 mmol/L EDTA
(pH 10.2). 125 µl xanthine oxidase (80 U/L) was added to
the mixture, and the increase of absorbance was followed
at 505 nm for 3 min. CuZn-SOD activity is expressed in U/
ml.
Erythrocyte GSH-Px activity was measured as previously
described by Aydin et al. [6]. Briefly, a reaction mixture
containing 1 mmol/L Na2EDTA, 2 mmol/L reduced glu-
tathione, 0.2 mmol/L NADPH, 4 mmol/L sodium azide
and 1000 U glutathione reductase in 50 mmol/L TRIS
buffer (pH 7.6) was prepared. 20 µl of erythrocyte lysate
and 980 µl of the reaction mixture were mixed and incu-
bated for 5 min at 37°C. The reaction was initiated by
adding 8.8 mmol/L hydrogen peroxide and the decrease
of absorbance recorded at 340 nm for 3 min. GSH-Px
activity is expressed in U/ml.
Lipid peroxidation was estimated by measurement of
thiobarbituric acid reactive substances (TBARS) in eryth-
rocyte lysates by the method previously described by
Aydin et al. [6]. After the reaction of MDA with thiobarbi-
turic acid, the reaction product was followed spectropho-
tometrically at 532 nm, using tetrametoxypropane as a
standard. The results are expressed as nmol/ml.
Statistical analysis
Statistical analyses were done by SPSS (Statistical Package
for the Social Sciences Program) 10.01 for Windows statis-
tical program. Independent-Sample T- test was used for the
comparison of the CHC patients and the control group.
Paired-Simple T-test was used for comparison of CHC
patients before and after the 48 weeks of pegylated inter-
feron alfa-2b, and ribavirin treatment. A value of two-
sided p < 0.05 was considered statistically significant.
Results
The results obtained show that the serum MDA is signifi-
cantly increased in selected group of CHC patients (n:19),
before pegylated interferon alfa-2b, and ribavirin treat-
ment when compared with healthy subjects (n:28) [(9.28
± 1.61 vs. 4.20 ± 1.47 nmol/ml, p < 0.001)] Table 1. These
results show that the patients with CHC are under the
influence of increased oxidative stress.
After 48 months treatment of all the CHC patients had
eliminated HCV-RNA and normalized serum transami-
nase. MDA concentration decreased significantly (p <
0.001) after pegylated interferon alfa-2b and ribavirin
Table 1: MDA, SOD, GSH-Px concentration and ALT, AST 
levels in the CHC patients before the treatment and the control 
group. (Mean ± Standard Deviation)
Control group (n:28) CHC Patients (n:19) 
Before Treatment
P-value
MDA 4,20 ± 1,47 9,28 ± 1,61 <0.001
CuZn-SOD 285,78 ± 96,46 213,84 ± 71,61 <0.05
GSH-Px 8,01 ± 1,79 6,52 ± 1,86 <0.05
ALT 21,53 ± 6,02 95.84 ± 22.68 <0.001
AST 22,50 ± 4,91 80.52 ± 19.27 <0.001
Values are shown as means, p values (<0.05) were derived by the 
Independent Samples T-test. Units were expressed as follows: MDA as 
nmol/ml; CuZn-SOD as U/ml,; GSH-Px as U/ml; ALT, AST as U/L.Page 3 of 6
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these patients (Table 2).
Treatment with pegylated interferon alfa-2b, 1.5 µg/kg
subcutaneous weekly and ribavirin 200 mg capsules
(dose: <75 kg BW: 2 caps in a.m. & 3 caps in p.m., >75 kg
BW: 3 caps in a.m. & 3 caps in p.m.) during 48 weeks, led
those patients whose ALT, AST activity normalized in
serum, to a concomitant decrease of the erythrocytes'
MDA content.
We compared the average superoxide dismutase level in
erythrocytes of patients with CHC before treatment
(213.84 ± 71.61 U/ml) with the average SOD activity in
control group (285.78 ± 96.46 U/ml) (p < 0.001). We
demonstrated that average SOD activity in patients with
CHC is significantly statistically lower (p < 0.05) than in
healthy control group.
The average glutathione peroxidase activity in erythro-
cytes of patients with CHC before treatment were 6.52 ±
1.86 U/ml. It was significantly statistically lower (p <
0.05) than average activity of GSH-Px in erythrocytes of
healthy control group (8.01 ± 1.79 U/ml). Table 1 shows
the activities of antioxidant enzymes in erythrocyte from
the CHC before treatment for patients, and for the control
group.
These findings in CHC patients before the treatment dem-
onstrated that antioxidant status was compromised with
several important components of the antioxidant defense
mechanism being significantly decreased.
Discussion
The reports from several studies have produced clear evi-
dence that there exists a good correlation between type
and severity of disease and antioxidant level in the blood
[7]. Although the main role of the immunological mech-
anisms in pathogenesis of the chronic viral hepatitis B and
C was demonstrated, researchers also concentrate on the
problem of oxidative stress in the pathology of the dis-
eases. Oxidative stress develops when the disturbances
between reactive oxygen forms are produced in excess and
the factors preventing their harmful effect occur. Enzy-
matic antioxidant defense of the organism includes: SOD,
CAT, and GSH-Px. Superoxide dismutase protects a cell
from toxic effect of superoxide radicals as it catalyzes the
dismutation reaction of the radicals [1]. Glutathione per-
oxidase decomposes hydrogen peroxide but it also con-
verts lipid peroxides to harmless molecules protecting the
cells from the consequences of lipid peroxidation. GSH-
Px removes H2O2 by the oxidation of reduced glutathione.
Oxidized glutathione (GSSG) is produced and it is
reduced again by glutathione reductase, and the NADPH
(produced in pentose cycle) [4].
Oxidative stress has been detected in almost all clinical
and experimental conditions of the chronic liver diseases
[8]. There are many studies about the oxidant stress in
chronic hepatitis C patients. De Maria et al. [9] showed
that MDA, a product of polyunsaturated fatty acid peroxi-
dation, was elevated in the liver and the blood. Paradis et
al. [3] also demonstrated MDA-protein adducts immuno-
histochemically in infected liver tissue. Boya et al. showed
that the peripheral blood mononuclear cells from patient
of chronic hepatitis C had increased MDA concentrations,
and enhanced SOD activity. MDA is reflection of lipid per-
oxidation and SOD is an important antioxidant defense
enzyme that converts superoxide into hydrogen peroxide.
Increased SOD activity appears to be an adaptive response
to increased generation of the superoxide ions [1].
Romero et al. showed higher serum malondialdehyde val-
ues in chronic hepatitis C patients than healthy subjects
before the interferon treatment [5].
Our results showed that serum MDA is significantly
increased in CHC patients before the treatment when
compared with healthy subjects (p < 0.001). The results
presented confirm the involvement of the oxidative stress
as a part of pathophysiology of CHC. Thus, our findings
support the existence of the oxidative stress in patients
with chronic HCV infection and are in agreement with the
studies mentioned above.
In our study MDA concentration decreased significantly (p
< 0.001) after pegylated interferon alfa-2b, and ribavirin
treatment as well as ALT, AST activity, in erythrocytes of
these patients. Romero et al. also demonstrated signifi-
cantly lower mean value of serum MDA levels after the
interferon treatment compared with the pre-treatment
levels [5]. Higueras et al. showed decrease in serum TBARS
content after treatment with 5 MU interferon, three times
a week during two months of chronic hepatitis C patients
[10]. We suggest the routine use of MDA assay as addi-
Table 2: MDA, SOD, GSH-Px concentration and ALT, AST levels 
in CHC patients before and after the treatment. (Mean ± 
Standard Deviation)
CHC Patients Before 
Treatment
CHC Patients After 
treatment
P-value
MDA 9,28 ± 1,61 4,88 ± 1,22 <0.001
CuZn-SOD 213,84 ± 71,61 357,94 ± 82,10 <0.001
GSH-Px 6,52 ± 1,86 9,47 ± 1,82 <0.001
ALT 95.84 ± 22.68 26,73 ± 10,65 <0.001
AST 80.52 ± 19.27 25,52 ± 8,68 <0.001
Values are shown as means, p values (<0.05) were derived by the 
Paired-Simple T-test Independent Samples T-test. Units were expressed 
as follows: MDA as nmol/ml; CuZn-SOD as U/ml,; GSH-Px as U/ml; 
ALT, AST as U/L.Page 4 of 6
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of this disease. The results presented confirm the value of
MDA as laboratory test in the management of liver dis-
eases and as a useful tool for observing the pathogenic
and/or the therapeutic mechanism of this viral infection.
Glutathione (GSH), the most abundant non-enzymatic
antioxidant present in the cell, plays an important role in
the defense against oxidative-stress-induced cell injury. In
the cells glutathione is present mainly in its reduced form.
Reduced GSH can be converted to oxidized glutathione
(GSSG) with the GSH-Px, which is revertible to the
reduced form with the glutathione reductase (GR). Cells
are also equipped with the enzymatic antioxidant mecha-
nisms that play an important role in the elimination of
free radicals [1].
Suarez et al. studied the group of 100 individuals with
chronic hepatitis C. He demonstrated GSH decrease in the
blood serum of patients who were not treated with inter-
feron. In contrast, GSH concentration was higher in the
blood of patients responding satisfactorily to the treat-
ment. The author set forth a theory explaining the cyto-
pathic effect of a virus causing glutathione deficiency.
Kramer et al. studied antioxidant enzymes and they found
diminished GSH-Px level in the blood serum and the
erythrocytes, in patients with abnormal liver function [4].
Pak et al. also demonstrated low activities of GSH-Px and
SOD in adults with acute hepatitis B [11].
Results of our study are consistent with the reports by Sua-
rez and associates. In the current study we demonstrated
that glutathione peroxidase level and superoxide dis-
mutase level are decreased in erythrocytes of patients with
chronic hepatitis C. It probably decreased the antioxidant
barrier efficiency in studied CHC patients. When the activ-
ity of the enzymes mentioned above is insufficient, an
organism is not capable to neutralize free oxygen radicals
that are produced in excess. It leads in consequence to
hepatocyte lesion [4].
Chrobot et al. demonstrated that SOD and catalase levels
decreased both in group of children with chronic hepatitis
C, and B. Kramer and associates studied the small group
of children with abnormal function of liver cell, and dem-
onstrated decreased activity of SOD in comparison to the
healthy children [4]. Loginow studied antioxidant system
in adults with chronic active hepatitis, and demonstrated
SOD decrease correlating with severity of inflammatory
process [12]. Study by Yasuyama et al. showed decrease of
SOD levels in liver tissue of patients with acute, and
chronic hepatitis accompanied by fatty degeneration
while comparing with patients with the liver inflamma-
tory diseases of different etiology [13]. In another study
Irshad et al. found SOD activity significantly low in the
chronic active hepatitis C patients [7]. On the contrary,
some author has detected high SOD levels in CHC
patients [1,2].
Similarly, our results showed that SOD was significantly
decreased in CHC patients before treatment when com-
pared with healthy subjects (p < 0.001). This result may
indicate decreased antioxidant capacity in chronic hepati-
tis C patients.
The reduction in the amount of SOD, and GSH-Px reflects
both a decrease in the synthesize capacity of liver, and the
antioxidant defense power of the patients with CHC. It
can be argued that increased lipid peroxidation is caused
by the inflammation related to viral infection and
decreased the antioxidant levels may be an early marker of
the oxidative stress. Lipid peroxides formed can be chem-
otactic for the neutrophils causing increased inflamma-
tion, which further drives oxidant-mediated injury in the
liver [14].
In the viral hepatitis, virus also infects the peripheral lym-
phocytes. The infected lymphocytes produce interferon to
stimulate healthy cells against viruses [15]. The pathoge-
netic mechanisms through which HCV causes cell damage
remain obscure, although it has been suggested that the
oxidative stress may play a pathogenetic role in this infec-
tion. The patients with chronic hepatitis C exhibit an
increased production of TNF-α, a cytokine that can pro-
duce oxidative stress by stimulating the generation of oxy-
gen ROS [2]. Although interferon and ribavirin are not
antioxidants, their antiviral capacity might reduce viral
load and inflammation and perhaps though this mecha-
nism might reduce virus-induced oxidative stress.
Several clinical trials have previously suggested a benefi-
cial effect of antioxidants in patients with chronic HCV
infections. Intravenous administration of glycyrrhizin, a
free radical scavenger, decreases elevated plasma transam-
inase enzymes, and improves histology in patients with
chronic HCV infections [16,17]. A combination of three
potent antioxidants (alpha-lipoic acid, silymarin, and
selenium) induced marked clinical, laboratory and histo-
logic improvement in chronic HCV patients [18,19]. The
results of the study by Melhem et al. suggest that antioxi-
dative treatment using a combination of multiple antioxi-
dants in patients with chronic HCV infections, may
ameliorate the inflammatory response as measured by
liver enzymes and liver biopsy inflammatory score [20].
Herbay et al. [21] observed that high vitamin E supple-
mentation improves the aminotransferase status in
patients who have chronic HCV. Murakami et al. demon-
strated that antioxidant vitamin (E and C) supplementa-
tion during interferon alfa-2b prevented decrease in
eicosapentaenoic acid of mononuclear cell phospholip-Page 5 of 6
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ids. It might be possible to enhance the efficacy of combi-
nation therapy of interferon alfa-2b and ribavirin [22]. In
contrast, Look et al. showed that adjuvant antioxidative
therapy by N-acetylcysteine/Selenium co-supplementa-
tion did not increase the antiviral response to six-month
interferon alfa monotherapy in chronic hepatitis C
patients [23].
As a conclusion, lower pretreatment levels of antioxidants
and higher level MDA level might be probable marker of
the oxidative stress. Reversal change of these levels with
completion of the treatment may indicate a correlation
between the oxidative stress and the viral pathogenesis.
Antioxidant supplement can be added in these patients
during their clinical survey. However, further investiga-
tions to highlight this issue are recommended.
Note
Chronic Hepatitis C patients after pegylated interferon
alfa-2b and ribavirin therapy showed values of SOD,
GSH-Px were significantly higher than pretreatment levels
(Table 2). MDA levels of patients with CHC were signifi-
cantly reduced while SOD and GSH-Px levels increased
after treatment. ALT, AST levels of the same group were
also reduced to the control levels after treatment.
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